New book by Larry Connors Click here Improve your trading - See how
Canadian Stocks to Watch:
Mansfield Minerals Inc. (TSX-Venture: MDR)
Mansfield is a mining exploration company which has focused its activities in northwestern Argentina since August 1994. The Company's current significant properties and projects consist of mineral rights covering approximately 170 square miles in three Argentine provinces and one Canadian province. The Company is currently focused on two primary projects which include Lindero (gold) and Rio Grande (copper-gold). Mansfield and Antares each own a 50% undivided interest in Rio Grande.
Greystar Resources Ltd. (TSX: GSL)
During 5 years of intense exploration, Greystar Resources Ltd. has outlined successively larger gold and silver resources at its wholly-owned Angostura Project in northeast Colombia. With a world-class resource in excess of 5 million ounces now estimated, Greystar is turning to the delineation of minable reserves with a view to undertaking a bankable feasibility study in 2001. 21% owned by Kinross Gold Corp. Through the subsidiary Greystar USA, Inc., Greystar acquired working interests in two natural gas prospects known as the Cottonwood Gulch Prospect (42.5%) and North Craig Prospect (35%) in Moffatt County, Colorado, USA.
You can view the Canadian Stocks to Watch in more detail by going here: http://www.allpennystocks.com/aps_ca/stocks2watch/stocks2watch.asp.
American Stocks to Watch:
Nanogen Inc. (Nasdaq: NGEN)
Nanogen provides innovative, high quality diagnostic products to clinicians, physicians and researchers worldwide, making it easier to predict, diagnose and, ultimately, help treat disease in a timely fashion. The company's products include molecular diagnostic kits and reagents and kits for rapid, point-of-care diagnostic tests. Nanogen has pioneered research in areas involving nanotechnology, biomarkers, and molecular biology to bring better results to diagnostics and healthcare.
pSivida Corp. (Nasdaq: PSDV)
pSivida is a drug delivery company committed to the biomedical sector, with a primary focus on ophthalmology and oncology. pSivida has two products approved by the Food and Drug Administration (FDA): Retisert® for the treatment of uveitis and Vitrasert® for the treatment of AIDS-related cytomegalovirus (CMV) retinitis. pSivida has licensed both of these products and the technologies underlying them to Bausch & Lomb Incorporated. pSivida has one product in fully recruited Phase III clinical trials: Iluvien™, which delivers fluocinolone acetonide (FA) for the treatment of diabetic macular edema (DME), formerly known as Medidur FA for DME. pSivida has licensed certain drug delivery technology to Alimera Sciences, Inc. for the development of Iluvien and certain other ophthalmic products. pSivida has a worldwide collaborative research and license agreement with Pfizer Inc. under which Pfizer may develop additional ophthalmic products.
You can view the American Stocks to Watch in more detail by going here: http://www.allpennystocks.com/aps_us/stocks2watch/stocks2watch.asp.
About AllPennyStocks.com Media Inc.:
AllPennyStocks.com is focused on the small-cap / penny stock market and has become a reputable name in the investment community. AllPennyStocks.com runs a Canadian and US site to provide investors in Canada as well as the United States with informative and unique content and information. AllPennyStocks.com runs weekly penny stocks to watch, has a daily market write-up, provides company spotlights, runs a unique most active pages strictly for penny stocks trading on the TSX, TSX Venture, Nasdaq and OTC BB, and much more information for the average investor.
AllPennyStocks.com has not received compensation for carrying the other above-mentioned companies; a full disclaimer can be viewed here: http://www.allpennystocks.com/aps_common/disclaimer.asp.
Contact:
AllPennyStocks.com Media, Inc.
Peter Szafranski - President
Phone: 905-361-5680
E-Mail: peter@allpennystocks.com
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
15260 Ventura Blvd., Ste. 2200
Sherman Oaks, CA 91403
© Copyright 2009 The Connors Group, Inc.
